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Cardiovascular disease is the number one killer worldwide, with myocardial infarction
(MI) responsible for approximately 1 in 6 deaths. The lack of endogenous regenerative
capacity, added to the deleterious remodelling programme set into motion by
myocardial necrosis, turns MI into a progressively debilitating disease, which current
pharmacological therapy cannot halt. The advent of Regenerative Therapies over 2
decades ago kick-started a whole new scientific field whose aim was to prevent or
even reverse the pathological processes of MI. As a highly dynamic organ, the heart
displays a tight association between 3D structure and function, with the non-cellular
components, mainly the cardiac extracellular matrix (ECM), playing both fundamental
active and passive roles. Tissue engineering aims to reproduce this tissue architecture
and function in order to fabricate replicas able to mimic or even substitute damaged
organs. Recent advances in cell reprogramming and refinement of methods for additive
manufacturing have played a critical role in the development of clinically relevant
engineered cardiovascular tissues. This review focuses on the generation of human
cardiac tissues for therapy, paying special attention to human pluripotent stem cells
and their derivatives. We provide a perspective on progress in regenerative medicine
from the early stages of cell therapy to the present day, as well as an overview of cellular
processes, materials and fabrication strategies currently under investigation. Finally, we
summarise current clinical applications and reflect on the most urgent needs and gaps
to be filled for efficient translation to the clinical arena.
Keywords: cardiac tissue engineering, human pluripotent stem cells, material properties, cell differentiation,
fabrication strategies
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A PERSPECTIVE ON CARDIAC DISEASE
AND REGENERATIVE MEDICINE
Organ transplantation is one of the greatest medical
achievements of the 20th century. However, its applicability
is hampered by donor shortage, life-long immunosuppression
and its success rates are linked to the experience of the surgical
team. It requires a well-coordinated national effort, which is
sometimes hindered by ethical issues (Prabhu, 2019). The search
for novel ways to approach organ repair inspired the field of
regenerative medicine, with Stem Cell Therapy as one of the most
representative examples. Since this began, stem cells have been
discovered even in low turnover adult tissues, such as the central
nervous system (Doetsch et al., 1999), the lung, (Rock et al., 2009;
Barkauskas et al., 2013) or the heart, (Beltrami et al., 2003) and
have been widely assayed in animal models of disease, quickly
reaching clinical trials. This swift progression in general met with
rapid failure, but on the bright side, it also enabled specialists to
gain immense insights into their mechanisms and ways of action.
Nothing exemplifies this journey better than the cardiac field.
Cardiovascular diseases are well recognised as the leading cause
of death worldwide, accounting for almost 1 in 2 deaths in Europe
and causing 3.9 million deaths per year (Townsend et al., 2016).
Ischemic heart disease (IHD) is one shade on this spectrum. It
is generally caused by the clotting of a coronary vessel, which
in turn leads to the death of a portion of the myocardium and
the subsequent functional impairment of the organ. Being mostly
non-regenerative, the heart is chronically impaired (Eschenhagen
et al., 2017). A real epidemic, IHD is the leading single cause
of death globally, responsible for over 15 million deaths in
2016, ranking first in high- and lower-middle-income countries,
and third in low-income countries (World Health Organization
[WHO], 2018). As per 2015, over 22 million EU citizens were
living with the disease, with approximately 3 million new cases
yearly. IHD imposes an enormous burden on society as affected
patients must be cared for by health systems, requiring lifelong
highly specialised medical attention and multimedication. It also
jeopardises the structure of the workforce and puts significant
pressure on families. In terms of economic cost, the total burden
of IHD for EU economies is estimated at €59 billion/year. Of
these, €19 billion is directly related to healthcare costs, while
€20 billion is linked to productivity losses and the remaining
€20 billion to the cost of indirect care. Estimations sketch out
a grim future. In the United States, heart attacks are projected
to contribute more than $818 billion to annual healthcare costs
and lost productivity by 2030, (Nowbar et al., 2019) while in the
South Asia region, direct medical costs for CVD are estimated
to reach US $16.6 billion in 2021 (Walker et al., 2018). Organ
transplant cannot match this overwhelming demand and become
a widespread therapeutic option (Stehlik et al., 2011).
It was hoped that cell therapy would provide new means
to regenerate the scarred myocardium. Remarkable discoveries
encouraged rapid progression towards clinical trials, with the
first one launched in record time (Behfar et al., 2014). After the
BOOST and REPAIR-AMI trials reported significant benefits in
cardiac function, (Wollert et al., 2004; Schächinger et al., 2006)
hundreds of patients were recruited often in individual efforts
mostly based on local experience. This led to the first voicing of
concerns. The primary initial objective, improvement of cardiac
function, failed to be met in many cases. Although statistically
significant benefits in cardiac function were sometimes found,
their magnitude was not as great as had been expected
(reviewed in Gyöngyösi et al., 2016; Menasché, 2018). This
reversal of fortunes coincided also with a remarkable twist in
our understanding of what basic science and animal models
conveyed: no true regeneration of the myocardium was achieved
by adult stem cells. The underlying effects were mostly due
to the paracrine secretion of beneficial molecules (Hodgkinson
et al., 2016). Although this general perspective is valid for most
adult stem cells, use of their embryonic counterpart, although
boosted by their capacity to give rise to new tissue once
transplanted, was still marred by some common issues such as
lack of proper engraftment, and crucially by safety concerns as
teratoma formation and need for immune suppression, as well
as ethical issues.
Did stem cell regenerative medicine approaches fail? They
obviously did not achieve the initial aims, but looking back,
those can no doubt be branded as overambitious (Pagano et al.,
2019). It did succeed in gathering a whole new compendium
of knowledge, which has led to renewed and better efforts
in the regenerative direction and, importantly, has built a
worldwide network of excellence encompassing not only different
nationalities, but also very diverse scientific disciplines. One
of the greatest and perhaps now evident realisations in the
field is the notion that cells are not alone in a tissue, and
that the extracellular matrix (ECM) has a predominant role,
not only as a passive architectural element, but crucially as a
signal transducer and determinant of functionality (Majkut et al.,
2013; Crowder et al., 2016; Kumar et al., 2017). Specifically in
the myocardium, the ECM is highly dynamic, changing during
development and disease. This latter change is bidirectional, as
disease induces pathological ECM deposition but an abnormal
matrix is able to produce malfunction (Frangogiannis, 2019).
In consequence, it is now recognised that a cell-based cardiac
regeneration without an adequate ECM is not viable. Generating
new myocardium thus requires the participation of the most
promising cells, with a surrounding matrix able to replicate the
conditions of the native tissue and the proper 3D architecture.
This is precisely one of the main directions of cardiac
Tissue Engineering.
Cardiac Tissue Engineering (cTE) is a highly interdisciplinary
scientific discipline, aiming at reproducing as accurately as
possible the function and biology of cardiac muscle, during
development or maturity, health or disease. Although its
first objective was focused on meeting the needs of cardiac
regenerative Medicine, as knowledge and experience on how the
ECM influences cardiac cell biology increased and the fabrication
capacities widened, its scope has greatly expanded into areas such
as disease modelling, drug testing and personalised medicine
amongst others (Feric et al., 2019; Noor et al., 2019; Mastikhina
et al., 2020). This review aims at presenting the reader with
an overview of the specific characteristics of the myocardium
that determine the needs regenerative cTE has to meet, as well
as providing a non-exhaustive revision of what the field has
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 2 August 2020 | Volume 8 | Article 955
fbioe-08-00955 August 9, 2020 Time: 12:3 # 3
Montero et al. Human Cardiac Tissue Engineering
delivered to attain this end, with a focus on human myocardium
and human pluripotent stem cells.
THE HEART
The mammalian heart is an incredible organ. Its main role is
to provide a continuous unidirectional supply of blood to the
organism. This comes at a stringent metabolic cost, consuming
the equivalent of 6 kg of ATP per day, with a complete renewal
of its ATP pool every 10 seconds. Most of this energy is obtained
through the oxidation of fatty acids in adulthood, though cardiac
metabolism is dependent on glucose during embryonic stages,
being able to employ lactate as a metabolic substrate (Neejy,
1974). Correct function is achieved through a specialised organ
architecture, dividing the heart into 4 chambers: atria, which
are smaller in size and muscular mass, receive blood and push
it out into the ventricles, which in turn pump either towards
the lungs or the body. In consequence, the left ventricle is
larger and has a thicker muscular wall than its right counterpart.
Chambers, inlets and outlets are separated by valves impeding
back flow. The heart is the first organ to function, around day
8 in mice and the 4th gestational week in humans (Brand, 2003).
It pumps continuously throughout life, efficiently ejecting blood
through an exquisite 3D structure, (Buckberg, 2002) established
by a complex set of embryonic movements, cellular growth
and incorporation (Günthel et al., 2018). Disruption of this
structure is seen in disease and can be in itself the cause of organ
malfunction: cardiac congenital defects and malformation are a
main cause of perinatal death, (Bressan et al., 2013) but also give
rise to many cardiomyopathies (McKenna et al., 2017).
Cardiac Embryonic Development: A Brief
Overview
The formation of the mammalian four-chambered heart
encompasses a series of tightly coordinated morphological,
cellular and molecular events (reviewed in Vincent and
Buckingham, 2010; Meilhac et al., 2014; Ruiz-Villalba et al.,
2016). Different pools of cardiac and extracardiac progenitors
are involved, including the mesoderm-derived First, Second and
Third Heart Fields (FHF, SHF and THF respectively) and the
Cardiac Neural Crest Cells (CNCCs). Cells of the FHF contribute
primarily to the left ventricle (LV) but there is also a small
contribution to the atria; SHF will form the right ventricle
(RV), outflow tract (OFT), atria and part of inflow tract (IFT);
(Buckingham et al., 2005). THF cells contribute to the sinus
node, some regions in the caval myocardium, and the Pro-
Epicardial Organ (PEO) (Mommersteeg et al., 2010; Bressan
et al., 2013). CNCCs arise from the dorsal neural tube, contribute
to the parasympathetic innervation of the heart, valves and
play a pivotal role in OFT patterning and optimal septation
(Keyte et al., 2014).
Early precardiac progenitors from the lateral mesoderm
have been mapped into the mid-anterior region of the
primitive streak, characterised by the presence of both anterior
Nodal/Activin and posterior bone morphogenetic protein (BMP)
signalling at low levels, (Zhang et al., 2008; Vallier et al., 2009;
Yamauchi et al., 2010; Yu et al., 2011) promoting the emergence
of cardiogenic mesodermal MIXL1 + KDR + cells. As a result
of these signalling gradients set in gastrulation, multipotent
cardiovascular progenitor (M) expressing the cardiac master
regulator MESP1 move in an anterior-lateral direction, forming
a horseshoe-like region termed the cardiac crescent or FHF
(Bondue et al., 2008; Chan S. S. K. et al., 2013). At a
molecular level, MESP1 induces the expression of the minimal
core of the essential cardiogenic transcription factors including
ISL1, TBX5, NKX2.5, and GATA4, in combination with the
chromatin remodeller SMARCD3 (BAF60C), which further drive
cardiomyogenesis (Vincent and Buckingham, 2010; Meilhac
et al., 2014; Meilhac and Buckingham, 2018). The cardiac crescent
fuses at the midline, forming the linear heart tube, which consists
of an interior layer of endocardial cells and an exterior layer
of myocardial cells separated by an acellular, ECM-rich space,
the cardiac jelly. Located central and dorsal to the FHF, SHF
cells remain in contact with the pharyngeal endoderm and in a
proliferative state as undifferentiated ISL1 + MEF2C + cells. As
development proceeds, SHF cells are added to the poles of the
heart tube, with the tube looping to position the different regions
into place. Chambers balloon out as a result of the differential
proliferation rates of CMs (Jong et al., 1997; Christoffels et al.,
2004). As already mentioned, THF cells (TBX18 + NKX2.5-)
contribute to the sinus node, caval myocardial cells and the PEO.
PEO-cells give rise to the epicardium, and some cells of this layer
undergo epithelial-to-mesenchymal transition to form epicardial
derived cells (EPDC), which will differentiate into vascular cells
(including the coronaries) as well as interstitial fibroblasts and
valvular cells, being essential for compaction (Pérez-Pomares
et al., 2002; Weeke-Klimp et al., 2010; Katz et al., 2012). Lastly,
CNCCs originate by delamination from the neuroectoderm,
(Hildreth et al., 2008) initially contributing to smooth muscle
cells and CMs, (Mjaatvedt et al., 2001) and making a significant
contribution to the innervation of the organ and to the OFT
(Hildreth et al., 2008; Sizarov et al., 2012). We refer the reader to
Table 1 for a full description of the mentioned gene abbreviations.
Post-birth Cardiac Development: Foetal
CMs vs. Adult CMs
Aside from the formation of the mammalian heart, CMs continue
to develop postnatally (Guo and Pu, 2020). Embryonic CMs
can beat spontaneously, express sarcomeric proteins and ion
channels, and exhibit action potentials and calcium transients
which are significantly distinctive from their adult counterpart
(Vincent and Buckingham, 2010; Meilhac et al., 2014). Human
and rodent embryonic CMs are around 30-40 fold less in size
and feature an irregular shape, in comparison with adult CMs
(Yang et al., 2014). These are characterised by an ultrastructural
organisation with a large mitochondrial volume and specific
mitochondria positioning between myofibrils. Sarcomeres in
postnatal CMs are long and well-aligned, in contrast to shorter
and disarrayed ones found in foetal CM. At a metabolic level,
embryonic CMs rely on glycolysis, whereas adult myocytes
preferentially consume fatty acids, a much more efficient energy
source. Myofibrillar protein isoform undergoes switching, being
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TABLE 1 | Full description of genes names.
Abbreviation Description
MIXL1 Mix Paired-Like Homeobox
KDR Kinase Insert Domain Receptor
MESP1 Mesoderm Posterior BHLH Transcription Factor 1
ISL1 Islet-1 LIM Homeobox
TBX5 T-Box Transcription Factor 5
NKX2.5 NK2 homeobox 5
GATA4 GATA Binding Protein 4
SMARCD3 SWI/SNF Related, Matrix Associated, Actin
Dependent Regulator Of Chromatin, Subfamily D,
Member 3
BX18 T-Box Transcription Factor 18
myosin heavy chain 7 (MYH7), myosin light chain 2 ventricular
isoform (MLC2v), cardiac troponin I3 (TNNI3) and a shorter
and stiffer Titin isoform, preferentially expressed in adult CMs,
in contrast to myosin heavy chain 6 (MYH6), myosin light chain
2 atrial isoform (MLC2a), and slow skeletal-type troponin I1
(TNNI1) on foetal CMs (Bedada et al., 2014). All these differences
directly correlate with contractile capacity, with adult CMs able
to generate more force than embryonic ones (Vincent and
Buckingham, 2010; Meilhac et al., 2014; Tan and Ye, 2018). For
example, strips of adult rat myocardium have been reported to
produce a peak twitch tension of 56.4± 44 mN/mm2, (Hasenfuss
et al., 1991) whereas collagen constructs with neonatal rat CMs
generated 0.4-0.8 mN/mm2 (Zimmermann et al., 2002). The
same difference in magnitude is believed to exist for human
cells, as comparisons with primary foetal human CMs are rare
(Yang et al., 2014).
The cardiac action potential and associated channels and
currents also distinguishes adult and foetal CMs. In immature
CMs, the expression of channels involved in repolarisation,
including potassium transient outward channels, L-type calcium
currents and the rectifying K + current (encoded mainly by
KCNJ2), is lower than in adult cells resulting in a less negative
resting membrane potential (−50mv ∼ −60 mv in embryonic
CMs) compared to normal (–85mv ∼ –90 mv in adult CMs)
(Zhang et al., 2009). Also, the pacemaker current If is present
in embryonic CMs but does not occur in adult myocytes
(Sartiani et al., 2007). The distribution of the gap junction
protein connexin 43 (Cx43) also plays an important role in
regulating electrical activity. While Cx43 concentrates at the
intercalated disc of adult CMs, it is circumferentially distributed
in immature CMs, which is not optimal for longitudinal electrical
propagation (Vreeker et al., 2014; Jiang et al., 2018). Adult
CMs have a well-developed sarcoplasmic reticulum (SR) with
a high level of SR-specific proteins like ryanodine receptor 2
(RYR2) and sarcoplasmic/endoplasmic reticulum Ca2 + ATPase
2a (SERCA2), (Ivashchenko et al., 2013) which, coupled with
the presence of transverse tubules (t-tubules), leads to a highly
coordinated Ca-induced-Ca-release and hence faster Ca transient
kinetics and amplitude when compared to foetal CMs (Louch
et al., 2015). Finally, where embryonic CMs are diploid, adult
CMs present different degrees of polyploidy, achieved through
DNA-synthesis without karyokinesis (Adler and Costabel, 1975;
Herget et al., 1997). Understanding how an embryonic CM
evolves into a mature cell is already proving fundamental in
human cTE. As the bioartificial tissues developed so far resemble
more their foetal counterpart, this insight is being incorporated
into the effort of driving engineered tissues towards an adult-like
functionality (Karbassi et al., 2020).
Heart Characteristics: What We Aim to
Engineer
Generating human myocardial surrogates in the laboratory
requires knowing what the natural composition and properties
of the organ are. The following paragraphs provide an overview
of what nature has achieved, specifically, what the main cellular
and extracellular components of the heart are, how they are
arranged in space, and importantly, what this means regarding
the resulting material properties (Figure 1).
Cellular Composition
As already explained, most cells forming the structure of the heart
are of mesodermal origin: CMs, vascular (endothelial and smooth
muscle) cells and fibroblasts. Others reside in the tissue but
are formed elsewhere, as immune cells, which play a significant
role in organ surveillance and disease. Deciphering the cellular
composition of the heart has been a very controversial subject,
be it in rodents or humans (Zhou and Pu, 2016). Histology can
determine that CMs are the largest fraction by volume. However,
numbers vary, with reports of murine myocytes being the largest
population by number [56/27/7 for CMs/fibroblasts/endothelial
cells respectively (Banerjee et al., 2007)] and others attributing
greater numbers to endothelial cells [43.6% vs 31% of CMs (Pinto
et al., 2016)]. Human proportions are similarly contradictory,
with some publications showing non-CM/endothelial cells are
the most abundant (Bergmann et al., 2015) and others endothelial
cells (Anversa et al., 1978). Furthermore, several studies have
reported varying cell proportions throughout the anatomical
regions of the organ (Sussman et al., 2002; Gaudesius et al.,
2003; Camelliti et al., 2004, 2005; Kohl, 2004; Baudino et al.,
2006). Things become more complicated if we take into account
the age of the individual, as some claim the final number of
myocytes is reached by one month, remaining constant over the
lifetime of the individual (Bergmann et al., 2015) whereas others
have reported a 3.4-fold increase in CM number between 1 and
20 years of age (Mollova et al., 2013). Other cell type numbers
change dynamically over time, with a reported 6.5-fold increase
in endothelial cells and an 8.2-fold increase for mesenchymal
cells (including fibroblasts) during heart growth. Interactions
between these cells are multidirectional and exert great influence
over crucial aspects of cardiac biology. Both endothelial cells
and fibroblasts are key for tissue function and homeostasis.
Aside from delivering oxygen and nutrients to the metabolically
demanding CMs, the endothelium is fundamental for tissue
hypertrophy and post-disease remodelling, (Holopainen et al.,
2015) and maturation, (Giacomelli et al., 2020) displaying a
strong paracrine influence (reviewed in Leucker and Jones,
2014). Fibroblasts also affect organ function and cell maturity,
(Woodall et al., 2016; Wang Y. et al., 2020) whilst other cell
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 4 August 2020 | Volume 8 | Article 955
fbioe-08-00955 August 9, 2020 Time: 12:3 # 5
Montero et al. Human Cardiac Tissue Engineering
FIGURE 1 | Main components of the mammalian heart. The two main constituents of the myocardium, cardiac cells and the surrounding ECM, both contribute to
and modulate the specific material properties of the tissue.
types, such as immune cells, have been reported to display direct
and significant interactions with CMs, as is the case with the
electrical coupling of macrophages with atrioventricular node
cells (Hulsmans et al., 2017). All in all, the general consensus
supported by unambiguous histological evidence is that CMs are
the largest fraction by volume, each nurtured by a median of 3
capillaries, where fibroblasts constantly keep the ECM through a
degradation-deposition equilibrium. This brings us to our next
player: the cardiac ECM.
ECM Composition
The cardiac cell types discussed above are arranged within a
glycoprotein matrix which supports and provides them with a
structure. Moreover, the cardiac ECM also has an active role in
transmitting contraction and avoiding hyper-stretching of CMs.
Its principal component is collagen, which accounts for 2–5% of
the total weight of the heart, mainly types I (89%) and III (11%).
Collagen type IV is present in the basement membranes, and
collagen type V is located in the pericellular space (Weber, 1989;
Eghbali and Weber, 1990; Sommer et al., 2015a). The collagen
matrix has classically been categorised depending on which
elements it tethers together into endomysium (binds adjoining
CMs), perimysium (aggregates myocytes into myofibrils) and
epimysium (present at the epicardial and endocardial surfaces).
Cardiac fibroblasts have been identified as the main cell type
responsible for secreting and remodelling the collagen matrix,
although CMs seem to contribute to collagen type IV deposition
(Eghbali et al., 1988). Apart from the structural function, the
collagen network makes an important contribution to the whole
myocardial tensile properties (Fomovsky et al., 2010).
Another key element of the cardiac extracellular matrix is
elastic fibres. These are composites, made of an elastin core
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surrounded by a myriad of microfibrils. They provide elastic
properties, by stretching upon mechanical demand and going
back to their original length once the load is removed. Hence the
importance of elastic fibres in tissues which have to accommodate
their structure, such as skin, arteries or lungs or the heart.
However, although elastic fibres are paramount for the heart’s
elasticity, other factors are known to have an influence upon
it, namely the proportion of muscle bundles to fibrotic tissue,
and the density of collagen crosslinking (Forrest and Jackson,
1971; Parmley et al., 1973). In fact, elastic fibres are found in
most cases close to the collagenous network and in intimate
association with it (Sato et al., 1983). Of note, mature elastic
fibres show slight architectural differences depending on the
tissue (Kielty et al., 2002). As aforementioned, elastin forms
the core of elastic fibres. Unlike most matrix proteins, which
undergo a constant/continuous deposition and turnover, in
healthy conditions elastin is synthesised only until adolescence
(Dubick et al., 1981; Burnett et al., 1982; Davidson et al.,
1982; Myers et al., 1985; Sephel et al., 1987; Parks et al.,
1988; Pollock et al., 1990; Ritz-Timme et al., 2003). Other
fundamental components of the cardiac matrix include, to a lesser
extent, laminin, fibronectin, proteoglycans and glycoproteins
(Fan et al., 2012). Laminin molecules are part of the basement
membrane and are thus in close contact with the cell, playing
an active role in modulating cell behaviour, including migration,
differentiation and phenotype stabilisation (Yap et al., 2019).
Fibronectin, besides promoting cell attachment, acts as an ECM
organiser and is involved in collagen deposition (Valiente-Alandi
et al., 2018). However, all components are crucial for tissue
integrity and function.
Many, if not all, cardiovascular diseases have repercussions
for the cardiac ECM. The reverse is also true. For instance,
infarction studies in pigs show that the collagenous network
starts to become disarranged after just 20 min of coronary
occlusion, whilst elastin begins to disappear after 40 min, and
both components appear detached from the basement membrane
after 120 min. The balance of collagens I and III has been
widely studied, revealing a significant increase in type III collagen
after myocardial infarction (MI) (Sato et al., 1983). Dilated
cardiomyopathies, in which the shape of the cardiac cavity
is abnormal, are at least partly related to aberrant collagen
remodelling, with less thick collagen and thinner fibres, which
results in weaker tensile properties, more muscle slippage and
wall thinning (Weber et al., 1988; Weber, 1989). Ventricular
hypertrophy consists of the thickening of the ventricular wall
associated with some conditions like hypertension, and it is found
together with overexpression of collagen in the form of interstitial
fibrosis (Eghbali and Weber, 1990).
Cardiac Architecture
In most tissues, structure and function are closely intertwined,
and the heart is no exception. However, certain aspects of
this relationship are still under debate. The overall manner
in which the heart contracts and pumps blood is known,
as is the arrangement of the tissue microstructure. The gap
lies in providing a theory that explains how the different
architectural elements interact to produce the global behaviour.
For example, there is an ongoing debate about whether the
myocardium forms a single myocardial band, (Buckberg et al.,
2015a,b) or the so-called myocardial mesh model is more
accurate (MacIver et al., 2018a,b). The controversy has two
aspects. On the one hand, there is no consensus on whether
the basic functional unit is the CM, or groupings of this
into bundles (groups of CMs), sheetlets (groups of bundles),
sheets (groups of sheetlets) or even laminae (groups of sheets).
On the other hand, although imaging techniques allow us to
visualise phenomena across the whole myocardium, it is not
feasible to ascertain the distinct contribution of the individual
functional units to producing the global outcome. According
to Buckberg et al., the CM can undergo six functional events:
shortening, lengthening, narrowing, widening, twisting and
uncoiling (Buckberg et al., 2015a, 2018). There are an estimated
2.5-10 billion cells (Bergmann et al., 2015) in the heart, each
of them performing one or more of these six actions in the
same or a different direction, and all we are able to see is the
macroscopic effect: a torsion-contraction movement of the organ.
Still under controversy, there are at least 7 proposed models
to accurately describe cardiac architecture, (Gilbert et al., 2007)
which is widely recognised to have a profound effect, whether
at a mechanical (LeGrice et al., 1995; Zócalo et al., 2008) or
electrical (Roberts et al., 1979; Taccardi et al., 2008) level. During
disease, myocardial architecture is severely disarranged, leading
to inefficient contraction (Roberts et al., 1987; Wickline et al.,
1992). It is expected that the application of advanced technology
like diffusion tensor MRI (DT-MRI), which can obtain highly
detailed information on fibre architecture, will soon shed light on
this debate (Scollan et al., 1998; Poveda et al., 2013).
At a simpler histological level, CMs (and CM
bundles/sheetlets) are arranged in different orientations
depending on their location in the organ, which in turn
determines the direction of the stress produced. Myocytes are
always in intimate contact with capillaries, which no doubt stems
from the high metabolic demand of an ever-working muscular
tissue: capillaries are located within 20 µm of CMs. Each CM is
surrounded by a basement membrane containing laminin and
collagen type IV, amongst others, and embedded in a highly
structured ECM where collagen type I, as already discussed, is the
main component (Figure 2). CMs connect to each other mainly
by intercalated disks at their ends, but also through side branches,
coupled to at least 2 CMs on the long axis and 1 laterally (Spach
and Heidlage, 1995). Intercalated disks contain gap junctions,
allowing fast current flow between neighbouring cells (Klabunde,
2012). As mentioned above, both individual CMs and groupings
of these are surrounded by enveloping collagen. Fibroblasts do
not participate in the electrical syncytium formed by the CMs,
but rather lie in the interstitial space.
Cardiac Biophysical Properties
When attempting to engineer a tissue, it is essential to carefully
recapitulate not only the cellular-extracellular components and
their architecture, but also the resulting biophysical properties.
These must reliably mimic those of their natural counterpart.
In the heart, material properties are very complex: not only
are they direction-dependent, but they also vary within the
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FIGURE 2 | Cardiac structure. The endocardial-to-pericardial structure is outlined, with the main cellular and extracellular components.
anatomical regions and the stage of the cardiac cycle. As an
example, the literature reports variations in stiffness between
the beginning and the end of diastole higher than an order of
magnitude. For human LV, the reported values are 10-20 kPa at
the beginning of the diastole, and 200-500 kPa at the end (Chen
et al., 2008). Contraction itself results in a significant stiffening:
from 0.5 to > 10 kPa. This magnitude is species-dependent,
with a reported 3-fold increase in mouse, (Jacot et al., 2010) 2-
fold in rat, (Prakash et al., 1999) and over 20 times in zebrafish
(Krieg et al., 2008). Development also leads to a stiffening in the
tissue, which arises from a relatively soft mesodermal layer (Krieg
et al., 2008). Disease severely stiffens the organ, mostly due to
the excessive deposition of collagen (scar for MI, interstitial in
hypertension or other conditions), with values of over 50-100 kPa
(Engler et al., 2008). Stiffness itself has a fundamental influence
on how efficient CM contraction is, with CMs on softer- or
stiffer-than-normal substrates doing little work or overstraining
themselves, respectively (Engler et al., 2008). Reports on cardiac
mechanical properties are extremely variable. This stems from
a mix-up of animal vs human, fresh vs fixed, and healthy vs
diseased data. In general, it is now accepted that most of the
heart’s passive mechanical properties are due to the collagen
in the matrix, (Sommer et al., 2015a) but at short sarcomere
lengths the protein titin is the predominant contributor (Nguyen-
Truong and Wang, 2018). Quoting Sommer et al., ‘results suggest
that the passive human LV myocardium under quasi-static
and dynamic multiaxial loadings is a non-linear, anisotropic
(orthotropic), viscoelastic and history-dependent soft biological
material undergoing large deformations’ (Sommer et al., 2015b).
Or in simpler words: it is very complex and with multiple
contributions from cellular/extracellular components. Added to
this, scales differ, depending whether the tissue is macroscopically
characterised using biaxial mechanical tests, (Sommer et al.,
2015b) or whether isolated CMs are probed at a cell-relevant
scale with Atomic Force Microscopy (AFM) (Andreu et al., 2014).
Furthermore, some conflicting results have been reported, from
reports showing force production from CMs to be increased
with increasing stiffness, (Bhana et al., 2010) to stiffness having
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no influence at all (Jacot et al., 2008). In fact and as explained
by Domian et al. (2017), it might even be the case that the
material properties of cardiac tissue are not the main actor in the
myocardial scenario, but this role is rather played by chamber
pressure. More experimental and theoretical work needs to be
done in this area before we reach a definitive conclusion.
Adding another layer of complexity, the heart has constant,
potent and highly relevant electrical activity. Sparking at a small
and specialised region called the sinoatrial node, the electrical
wave travels through the auricles, reaching the atrioventricular
node where it is delayed (allowing for the filling of the
ventricles), and then spreads apex-to-base through the ventricles
in a coordinated manner. All this process is controlled by a
singular CM type, termed pacemaker cell, displaying disarrayed
sarcomeres and low work generation capacity, but able to
autonomously start the cardiac action potential. Ultimately, the
action potential results in the entry of Ca+2 ions into the
CM, releasing the sarcoplasmic stores of Ca+2 and freeing
myosin of the inhibitory action of troponin I. CMs are also
electrically connected through connexins, which form bridges
between the cytoplasm of adjacent myocytes, effectively making
the myocardium an electrical syncytium. However, it is an
anisotropic one, with faster propagation in the direction of the
fibres as opposed to the transverse direction (Chung et al., 2007).
Conduction velocity is the speed with which the cardiac impulse
travels from one point in the tissue to another. In adulthood,
it lies in the range of 0.3-1 m/s, but developmental stage and
disease will affect it (Yang et al., 2014). Achieving a similar value
in any cardiac engineered tissue is paramount, given the fact
that a mismatch between conduction velocities may give rise
to potentially fatal electrical abnormalities such as arrhythmias
(Kadota et al., 2013; Zhang et al., 2018). It is interesting that
one of the foci in cTE is towards providing material-based
electronic conductivity, although cardiac cells do not function by
transmitting electrons but ions.
As mentioned already, both the mechanical and electrical
properties exert a strong influence upon myocardial biology and
function, in both health and disease. For example, increased
fibrosis due to pathological conditions like MI or hypertension
significantly stiffens cardiac muscle and affects CM contraction
(Sessions and Engler, 2016). Ventricle loading induces CM
elongation which, as explained by the Frank-Starling law,
renders higher stroke with increase diastolic filling (Solaro,
2007). The coordinated conduction of the depolarisation wave
throughout the organ, including the atrioventricular delay
and the apex-to-base transmission, all contribute to optimal
functionality and must be taken into account when engineering
a human myocardium.
ENGINEERING CARDIAC TISSUE: THE
BUILDING BLOCKS
cTE aims to generate tissue surrogates, either micro or macro,
for various purposes, from developmental biology, (Young and
Engler, 2011) to therapy (Miyagawa et al., 2018). In the following
paragraphs, we will outline the main cells and materials, as well as
the different fabrication technologies assayed in the field and the
procedures for their maturation. Table 2 summarises some of the
most relevant engineered myocardium examples, with a focus on
human cardiac tissue.
Cells
The capacity to obtain human cardiac cell phenotypes in the
laboratory began with the derivation of human embryonic stem
cells (hESC) by Thomson and colleagues in 1998, (Thomson
et al., 1998) which was soon followed by the first protocols for
differentiation towards CMs (Mummery et al., 2003; Kattman
et al., 2006). In 2006, thanks to the breakthrough of the
reprogramming technology (Takahashi and Yamanaka, 2006; Yu
et al., 2007) it became possible to relieve the field of some of
its most notorious encumbrances, including the ethical ones.
Both, hESCs and human induced pluripotent stem cells (hiPSC)
fall within the wider category of human pluripotent stem cells
(hPSC). Current methods, including scaling up protocols, (Serra
et al., 2011) have paved the way for their widespread use. In
general direct, efficient and reproducible hPSCs differentiation
methods try to recapitulate embryonic development, from the
induction of cardiac mesoderm, to CM, endothelial cells (ECs),
cardiac fibroblast (CFs) or smooth muscle cells (SMCs) in vitro
specification and maturation (Figure 3) (Burridge et al., 2015).
According to the culture format employed, derivation of
CMs, CFs, ECs and pericytes/SMCs from hPSCs can be
categorised into 3 main approaches: (i) inductive co-culture
with visceral endodermal-like cells, (ii) suspension aggregates
such as three dimensional (3D) embryoid bodies (EBs) and (iii)
two-dimensional (2D) cell monolayer differentiation (Mummery
et al., 2003; Kattman et al., 2006; Laflamme et al., 2007; Moretti
et al., 2010). Early reports showed that co-culturing hPSCs with
the mouse endodermal cell line END2 was able to induce beating
foci (MacIver et al., 2018a). The low efficiency of this method,
as well as the need for xenogenic co-culture, precluded its
widespread application. EBs are formed by culturing dissociated
hPSC in non-adherent plastic dishes and partially recapitulate
the 3D structure and interactions of a developing embryo. hESC-
EBs differentiate to derivatives of the three primary germ layers,
resulting in spontaneously contracting outgrowths of human CM
(Kehat et al., 2001). Based on EB differentiation protocols, CM
from a variety of hESC and hiPSC lines have been generated,
usually with a purity of < 10% (Zhang et al., 2009). ECs can
also be isolated from spontaneously differentiating EBs, at a
similarly low yield (≈2%) (Levenberg et al., 2002). In both
cases, early reports explored the addition of cardiac mesoderm-
inducing growth factors, including FGF2, VEGF BMP4, Activin
A, Wnt agonists (WNT3A) or antagonists (DKK1), amongst
others (Yuasa et al., 2005; Kattman et al., 2006, 2011; Yang et al.,
2008; Tran et al., 2009; James et al., 2010). In general, however,
EB-based differentiations have lost ground to more advanced
and defined procedures, as the former are generally inefficient
and render a mixture of cardiac cells with other non-cardiac
phenotypes, requiring additional purification.
Monolayer-based differentiation is nowadays the most usually
applied method. Cytokine-based protocols were developed first
(Taccardi et al., 2008). These have been progressively modified



















TABLE 2 | Summary of materials, cells and methods employed to engineer cardiac tissues, their biomimicry and resulting outcome.
REF Materials Fabrication Cellular mimicry Material mimicry Maturation Benefit of the selected approach?
Hydrogel Fibres CM EC SMC CF Mech. Elect. Align Mech Elec vs. Gene exp. Structure Function
Godier-Furnémont et al., 2015 Col I – Mould casting Rat neonatal Yes No No + + NM nd + +
Hirt et al., 2014 Fibrin . Mould casting Rat neonatal Yes No No + + EHT + + +
Jackman et al., 2018 FGN – Mould casting Rat neonatal Yes No No + – NM + + +
Amdursky et al., 2018 Albumin – Mould casting Rat neonatal Yes No No – – 2D + + –
Nunes et al., 2013 Col I – Mould casting hPSC + – – – + NM + + +
Ruan et al., 2016 Col I – Mould casting hPSC + – – + + EHT + + +
Tiburcy et al., 2017 Col I – Mould casting hPSC FK + – – + – 2D nd + +
Valls-Margarit et al., 2019 Col I + ELN – Mould casting hPSC FK + – – + + 2D nd + +
Zhang et al., 2013 Fibrin – Mould casting hPSC nd – – – – 2D + + +
Hirt et al., 2014 Fibrin . Mould casting hPSC + – – + + EHT + + +
Weinberger et al., 2016 Fibrin – Mould casting hPSC hPSC + – – + – NM nd – –
Ulmer et al., 2018 Fibrin – Mould casting hPSC + – – + – 2D – + nd
Ronaldson-Bouchard et al., 2018 Fibrin – Mould casting hPSC DF + – – + + 2D + nd nd
Jackman et al., 2016 FGN – Mould casting hPSC + – – + – NM nd + +
Shadrin et al., 2017 FGN – Mould casting hPSC hPSC hPSC + – – + – NM + – +
Dattola et al., 2019 PVA* – Foaming + FD hPSC + – – – – 2D nd – nd
Han et al., 2016 – PCL SE hPSC – – + – – 2D + + –
Joanne et al., 2016 – Col I SE hPSC + – – – – NM nd + +
Sireesha et al., 2015 – POCS–FGN SE hCM + – – – – 2D nd + nd
Khan et al., 2015 – PLGA SE hPSC – – + – – 2D – + –
Roshanbinfar et al., 2020 – Col I/HA/PANi SE hPSC + + – – – EHT nd + +
Macqueen et al., 2018 – PCL/Gelat Pull spinning hPSC + – + – – 2D nd + +
Castilho et al., 2018 Col I PCL MEW hPSC – – – – – 2D + + nd
Vaithilingam et al., 2019 PETra + MWCNT 3DP–SLA hPSC No + + – – 2D nd + nd
Lee et al., 2019 Col I – 3DbioP hPSC CF + – – – – NM nd + –
Maiullari et al., 2018 FGN/PEG – 3DbioP hPSC HUVEC nd – – – – EHT nd + nd
Noor et al., 2019 dECM – 3DbioP hPSC hPSC + – – – – NM nd + +
Arai et al., 2018 – – 3DbioP hPSC HUVEC DF nd – – – – EHT nd + nd
REF, Reference; CM, Cardiomyocyte; EC, Endothelial cell; SMC, Smooth muscle cell; CF, Cardiac fibroblast; Mech, mechanical; Elec, electrical; Gene exp., Gene expression; Col I, collagen type I; FGN, Fibrinogen; hPSC,
human pluripotent stem cell; FK, Foreskin fibroblast; DF, Dermal fibroblast; PVA, poly-vinil-alcohol; FD, Freeze-drying; ∗, foam; SE, Solution electrospinning; POCS, poly[1,8-octanediol-co-(citric acid)-co-(sebacic acid)];
hCM, primary human CM; PLGA, polylactide-co-glycolide; PCL, polycaprolactone; Gelat, Gelatin; PETrA, pentaerythritol triacrylate; MWCNT, Multi-walled carbon nanotubes; 3DP,3D Printing; SLA, Stereolithography;
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FIGURE 3 | Cardiac differentiation of hPSC. hPSC differentiation in vitro mimics embryonic development. Induction signals, main molecular pathways and lineage
markers are outlined.
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by the discovery of Wnt signals playing a biphasic role in cardiac
differentiation in vivo, (Marvin et al., 2001; Ueno et al., 2007) with
early signals directing hPSCs towards cardiac fate, whilst later
inhibition of those signals is a prerequisite for CM specification.
Almost 10 years ago, this concept was incorporated into the CM
differentiation from hPSCs, (Lian et al., 2012) paving the way for
the grounding of a chemically defined procedure (Burridge et al.,
2014). Based on small molecules rather than cytokines, and thus
less costly, this protocol is now widely applied, providing highly
pure yields of hPSC-derived CMs when in combination with a
metabolic-based selection (Tohyama et al., 2013). This means
that complicated and inefficient EB-forming procedures or
expensive and time-consuming immune-selection protocols have
now been discarded (Burridge et al., 2007; Hattori et al., 2010;
Elliott et al., 2011; Uosaki et al., 2011). However, even this latest
protocol still requires a degree of set up to avoid inconsistent
efficiencies amongst cell lines and experimental repeats, mostly
related to different patterns of endogenous early canonical Wnt
expression (Paige et al., 2010). In general, CMs obtained from
these protocols consist of a mixture of pacemaker, atrial and
ventricular myocytes, though some researchers consider that this
is open to question, as hPSC-CMs are immature and intrinsically
plastic (Du et al., 2015).
The derivation of other cardiac phenotypes has been also
achieved, with a variety of protocols now available. Palpant et al.
reported the generation of CMs, cardiac- or hemogenic-derived
ECs as well as blood cells by finely dosing BMP4 and Activin
A in order to pattern hPSC towards different mesodermal fates
(Palpant et al., 2017). Others have employed a mixture of small
molecules and cytokines to derive vascular cells from hPSCs in
monolayer culture with high efficiency (Orlova et al., 2014; Patsch
et al., 2015). Global gene transcription analysis has demonstrated
low variability between ECs differentiated via cytokine-based
methods from multiple lines of hPSCs (White et al., 2013). CFs,
have been increasingly recognised as major players in cardiac
development and homeostasis, having a similarly significant
effect upon the capacity to build cardiac tissues in the lab.
Recently, two independent groups have reported the generation
of hPSC-derived CFs, giving also proof of their capacity to affect
hPSC-CM function (Zhang H. et al., 2019; Zhang J. et al., 2019).
Epicardial cells have similarly been derived, (Witty et al., 2014)
demonstrating their ability to increase the therapeutic capacity
of hPSC-CMs in vivo (Bargehr et al., 2019). Finally, sinoatrial
node pacemaker CMs have been obtained from hPSC, and their
capacity to pace tissues in vivo has been reported (Protze et al.,
2017). Other approaches to the differentiation of cardiac lineages
include the generation of CVPs, (Blin et al., 2010; Birket et al.,
2015; Zhang Y. et al., 2016) or direct reprogramming strategies,
(Mohamed et al., 2017) but they have rarely been explored in cTE.
Materials
In parallel to the way differentiation of hPSC mimics the natural
embryonic development, the current view is that the more a
material replicates the properties of cardiac tissue, the higher the
chances of success. Development over the last 15 years has yielded
a wide portfolio of materials and biomaterials. Classifications
are numerous, be it by origin (natural, synthetic or hybrid),
crosslinking (chemical vs physical), size (macro, micro or nano),
polymerisation mechanism (enzymatic, light-triggered or pH-
responsive) or whether they are or not reinforced with other
structures like fibres. For specific insight into these classifications,
we direct the reader towards some of the excellent latest papers
(Peña et al., 2018; Liu et al., 2019; Xu et al., 2019). One of the most
relevant classifications is, however, on the physical consistency
of the applied material, where we can differentiate (i) injectable
materials and hydrogels, (ii) solid or fibrous scaffolds and (iii)
composite systems.
Hydrogels are probably the most widely explored type of
material in cTE. Collagen, being the main component of the
cardiac ECM, has been widely employed (see the following
sections). It can be readily isolated from animal or even human
tissues in sufficient quantities, extracted and solubilised, although
it requires acidic pH for this. Therefore, a careful control over
pH is needed for optimal polymerisation and embedded cell
survival. Gelatin, being denatured/digested collagen, has also
been intensely explored and the basis for the generation of some
of the most applied semi-synthetic materials, such as gelatin
methacryloyl (GelMA)(Yue et al., 2015) and several biorthogonal
derivatives (Koshy et al., 2016; Bertlein et al., 2017). Alginate, a
sugar-based natural hydrogel obtained from algae, (Orive et al.,
2006) has been employed due to their tailorable mechanical
properties and simple polymerisation, mediated by cations such
as Ca or Mg, albeit lacking biological binding motifs. Silk and
its derivatives have also been processed into hydrogels, (Holland
et al., 2019) and modified to incorporate electrically active
particles (Barreiro et al., 2019) or photocrosslinkable chemical
groups (Cui et al., 2020). Allergic and anti-inflammatory side
reactions have been reported with some silk derivatives, so care
should be taken when incorporating them into an engineered
tissue. Amongst natural hydrogels, decellularised ECM (dECM)
has attracted significant interest since the breakthrough discovery
of the process, as applied to the building of tissues (Ott et al., 2008;
Belviso et al., 2020). In principle, dECM retains all components of
the ECM of origin, thus creating a more complex and biomimetic
environment. Garreta et al. obtained human dECM slices on
which they cultured hPSC-CMs. The human CMs demonstrated
enhanced conduction velocity and gene expression of related
genes (SERCA, KCNJ2, CACNA1C or SCN5A amongst others)
(Garreta et al., 2016). The group of Lior Gepstein employed
dECM-chitosan mixtures in combination with hiPSC-CMs. The
resulting engineered myocardium displayed enhanced maturity
as compared with cells cultured in 2D, showing tissue-like drug
responses. Their work also provided proof-of-concept of the
capacity of this system to model human cardiac diseases (Long
QT syndrome) and arrhythmias (Goldfracht et al., 2019). On
the synthetic side, polyethylene glycol (PEG) and its several
modifications have been extensively studied in the TE field
(Iyer et al., 2009).
Most of the materials so far outlined in this section can
be processed into fibres employing strategies explained in the
next section. Thermoplastics have also been applied to cTE,
mostly as fibrous scaffolds. Examples include poly-ε-caprolactone
(PCL), (Woodruff and Hutmacher, 2010) or elastomers like poly
(glycerol-sebacate) (PGS) (Kharaziha et al., 2013). Conductive
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polymers have only recently began to be applied to the field,
though some of the most remarkable examples have not
incorporated the use of cells and would therefore not qualify
as engineered tissues (Mawad et al., 2016; Kapnisi et al., 2018).
Finally, given the low mechanical properties displayed by most
hydrogels, composite fibre-reinforced materials are also being
developed, (Bas et al., 2015) with some examples explained in the
following section.
Maturation Stimuli
Cells derived from hPSC are immature (see Karbassi et al., 2020
for a review). Although not the direct focus of this work, neonatal
myocytes, which are another cell source commonly employed,
also suffer from this drawback. cTE has long been aware of this
limitation and has applied three main stimuli, namely physical,
mechanical and electrical, and combinations thereof Parsa et al.
(2016) and Stoppel et al. (2016). Perfusion is able to improve
engineered tissues’ properties, as it will boost nutrient access and
renewal, as has been shown for neonatal cells (Radisic et al.,
2004b) as well as hiPSC-cardiac derivatives (Valls-Margarit et al.,
2019). Materials’ physical properties (e.g., stiffness) are able to
induce maturation features in these CMs, or at least preserve
primary CMs from dedifferentiation (Amdursky et al., 2018). In
general, most hydrogels are able to replicate the right myocardial-
like properties. For example, Feaster and colleagues found that
plating hiPSC-CMs on thick Matrigel induced a certain degree
of molecular and functional maturation, in comparison to thin,
diluted hydrogel coating, which essentially transmits the rigidity
of the underlying plastic (Feaster et al., 2015). Herron et al.
employed soft (albeit supra-cardiac) substrates and compared
them with glass in their capacity to influence hiPSC-CMs, with
a significant effect on maturation, showing improvement in the
expression of Na and K channels, as well as on the degree of
binucleation, cell cycle exit and hypertrophy (Herron et al., 2016).
Although not purely based on engineered tissues, they and others
give proof of the crucial role stiffness plays in cardiac maturation.
Mechanical stimulation has a leading role in cardiac
development and aging (Happe and Engler, 2016; Sessions
and Engler, 2016). It can be isometric, isotonic or auxotonic
(Liaw and Zimmermann, 2016). In isometric stimulation, the
construct is preloaded and must exert force against a static
load. In isotonic stimulation, a device will cyclically exert
active elongation on the engineered tissue. Finally, auxotonic
stimulation occurs when the myocardial tissue has to contract
against a resilient load. In principle, the auxotonic mode confers
a more physiological stimulation, although all three are reported
to deliver maturation upon engineered myocardium (Godier-
Furnémont et al., 2015; Lux et al., 2016; Ruan et al., 2016;
Ulmer et al., 2018). Although the exact mechanisms by which
mechanical stimulation matures the cardiac engineered tissue are
not known in depth, it is presumed that they will operate by the
same ones occurring during cardiac development or physiologic
hypertrophy (Nakamura and Sadoshima, 2018). After all, being
a striated muscle, the myocardium can undergo hypertrophy if
exercised (Kim et al., 2008).
As an electro-sensitive organ, the heart can be stimulated by
electrical pulses, which can help maintain its function ex vivo
(Watson et al., 2019). Electrical stimulation is known to have
a relevant effect on hPSC-CM differentiation and maturation.
Over 20 years ago, Sauer et al. established a relationship between
this stimulation and mouse ESC differentiation to CM (EB
method). They showed the effect was at least partly mediated
by reactive oxygen species (ROS) generation and NF-κB, and
could be replicated by ROS from H2O2 incubation (Sauer
et al., 1999). Serena et al. analysed the effects of the type of
electrode and stimulation length on CM differentiation via the
EB method from hESC, finding a role for ROS, though the
effect on the efficiency of differentiation was not determined
(Serena et al., 2009). Hernández et al. employed brief (5 min)
electrical stimulation, of hiPSC-EBs, finding an increase in the
percentage of cardiac differentiation (% of beating EBs) after
14 days (Hernández et al., 2016). However, the use of the
EB method complicates findings, as the effect could also be
mediated by other cell types within the EB. Electrical stimulation
has also been shown to enhance hPSC-CM maturation at the
gene expression and functional levels (Ca transients), as well as
promoting the ventricular phenotype (Chan Y. C. et al., 2013).
Reasoning that exogenous electrical stimulation would act as
an artificial pacemaker, Richards and coworkers evaluated the
implementation of electrically conductive silicon nanowires in
hiPSC-derived cardiac spheroids, showing that it was able to
improve CM-to-CM communication (measured by staining for
Connexin 43 and N-cadherin) and structural quality, though
some of these quantifications might nowadays be regarded as
debatable (Richards et al., 2016). The cTE field has implemented
electrical stimulation to cardiac constructs with success. The
group of Gordana Vunjak-Novakovic pioneered work in this
area, showing the enhanced of contraction (synchronicity) and
structure (alignment, ultrastructure) on neonatal rat CMs seeded
on Ultrafoam collagen sponges and Matrigel (Radisic et al.,
2004a). The group developed stimulation protocols as well as
bioreactors, (Tandon et al., 2008, 2009; Massai et al., 2013)
which have influenced the whole field. The group of Milica
Rasidic built hPSC-based cardiac tissues by embedding hPSC-
dissociated EBs in collagen type I and Matrigel. After electrical
stimulation, they showed an increased myofibril ultrastructural
organisation and improved function (conduction velocity and
Ca handling properties) as compared to non-stimulated controls
(Nunes et al., 2013).
Finally, some remarkable advances have been made when
combining electrical and mechanical stimulation. Ruan et al.
generated collagen-based cardiac engineered tissues containing
hPSC-CMs, which were subjected to electromechanical
stimulation and compared to static stretch or no stimulus.
Results showed a positive Frank-Starling effect (increased
force production with increased preload), a less negative
force-frequency relationship (increased force production with
increased pacing frequency) and maximum stress generation
for the electromechanical stimulation group, which was
correlated with increased expression of RYR2 and SERCA2,
thus supporting the use of combined stimulation for enhanced
maturation (Ruan et al., 2016). The group of Dr. Zimmermann
employed auxotonic stimulation delivered through stretchers
in combination with electrical pacing at 0, 2, 4, or 6 Hz
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(Godier-Furnémont et al., 2015). Results on tissues generated
with collagen and neonatal rat cells showed that the 4 Hz
regime was able to generate tissues with a physiological and
positive force-frequency and enhanced functionality. Also, the
presence of T-tubules was demonstrated. Finally, the group of
Prof Vunjak-Novakovic generated hiPSC-CM-based collagen
tissues on flexible stretchers (auxotonic mechanical stimulation)
and supplied no stimulation (control), 2 Hz and 0.33 Hz/day
progressive increase over 2 weeks (‘intensity training’). Their
results demonstrated the effectiveness of this strategy, as
shown by a physiological sarcomere length, increased density
of mitochondria, T-tubules, a more mature metabolism and
functional improvements at the level of Ca cycling and a positive
force-frequency relationship (Ronaldson-Bouchard et al., 2018).
Fabrication Strategies
Materials confer cTE with significant options, not only due to
the available range, but also through the application of different
fabrication modalities, which can deliver different properties out
of the same starting material. For example, collagen can be
mould-casted, (Godier-Furnémont et al., 2015) extruded, (Araña
et al., 2014) or bioprinted, (Lee et al., 2019) and the resulting
properties will vary widely, with casted and bioprinted collagen
having a stiffness in the range of kPa, whilst the extruded
film will be significantly stiffer (MPa). In addition, structure
will also differ. 3D printing and bioprinting have no doubt
revolutionised our capacity to engineer cardiac tissues, however,
other technologies can provide relevant features. The following
paragraphs outline some of the most employed strategies,
classified depending on their capacity to produce a controlled
architecture (Table 3).
Techniques With No True Architecture Control
Mould casting
Probably the simplest and most widely employed fabrication
mode, requires the generation of a mould of the desired
shape, and is the fabrication technique of choice in many
biomedical-based laboratories, where other methods could not
be implemented due to lack of expertise or specific equipment.
It does not provide much control over the resulting architecture,
but can be combined with others, like porogen leaching, to add
specifically selected features to the resulting tissue. The first
reports on engineered cardiac tissues by Thomas Eschenhagen
and coworkers in the late 1990s were developed by mould-casting
a mixture of chick embryonic CMs embedded in a collagen
solution. This was allowed to gel between two Velcro-coated
glass tubes. The resulting tissues, later termed engineered heart
tissues (EHTs), could be cultured in vitro and maintained over
several days, responded to electrical stimulation, displayed a
positive Frank-Starling relationship, were sensitive to levels of
extracellular calcium, and could be modified with viral vectors
(Eschenhagen et al., 1997; Zimmermann et al., 2000).
Since then, the technology has evolved enormously. It was
expanded to neonatal rat cells, (Zimmermann et al., 2002) and
refined, with the possibility of fabricating more complex and
thicker EHTs, which functioned synchronously (Zimmermann
et al., 2006). These stacked EHTs also showed promise as
a therapy when transplanted in a rat model of infarction.
EHTs have been employed by the groups of Eschenhagen and
Zimmermann, either fibrin- or collagen type I-based, to study
the effect of chronic stretch on CM hyperthrophy, (Fink et al.,
2000) as a disease model of hypertrophic cardiomyopathy, (Stöhr
et al., 2013) or to analyze the effect of electrical stimulation (Hirt
et al., 2014). EHT technology has greatly benefited from the
implementation of hPSC-derived cells, as the findings, models
and application have gained greater impact, be it as a drug
testing platform (Eder et al., 2016), an in vitro tool to study
cardiac stimulation, (Godier-Furnémont et al., 2015) or as a
potential myocardial regenerative therapeutic (Weinberger et al.,
2016; Tiburcy et al., 2017). The Bursac group has also employed
mould casting of rat and human (hiPSC-derived) cells to engineer
cardiac tissues and explore different strategies to mature them
in vitro (Jackman et al., 2016). They applied this strategy to
fabricate tissues up to human scale, though thickness was limited
by nutrient and oxygen diffusion. When assayed in a rat model
of disease, their cardiopatches retained integrity after 3 weeks,
showing extensive vascularisation by host-derived vessels and
maintaining electrical activity, although they did not functionally
integrate with the endogenous myocardium (Shadrin et al., 2017).
The team of Milica Radisic employed PDMS moulds to form
engineered cardiac tissues around a surgical suture, composed
of hPSC-derived cardiac cells, collagen type I and 10% Matrigel
(Nunes et al., 2013). By employing electrical stimulation, through
carbon rods immersed in the culture medium, they were able
to drive the hPSC-CMs towards a more mature phenotype and
functionality. This system was later applied also to drug testing
(Feric et al., 2019). Finally, one of the most advanced pieces
of evidence for hPSC-CM maturation in vitro was provided
by the group of Gordana Vunjak-Novakovic, as explained in
the previous section (Ronaldson-Bouchard et al., 2018). They
employed a 3:1 mixture of hPSC-CMs and dermal fibroblasts
embedded in a fibrin matrix, cast into wells where flexible PDMS
posts were also included. These conferred pre-tension on the
generated engineered myocardium, thus adding physiological-
like auxotonic stimulation (Mannhardt et al., 2019). A set of
custom-made carbon electrodes delivered electrical stimulation.
The resulting bioartifical myocardium displayed adult-like gene
expression profiles, ultrastructural features such as M-bands
and T-tubules, as well as oxidative metabolism and mature
functionality. In summary, although mould casting cannot
generate fine features, it is one of the most widely applied and
highly evolved methods to obtain human mature cardiac tissue,
and the one closest to translation.
Macro-to-micro pore-forming strategies
Cryogelation, based on freeze drying, is a common preservation
strategy that is also applied to TE. The pre-crosslinked material
is subjected to freeze-thawing cycles, which induces ice crystal
formation. These crystals act as porogens, to be removed
when pressure is decreased and the solvent sublimated. In
general, pores are well inter-connected, as demonstrated early
on by O’Brien and colleagues for collagen-glycosaminoglycans
scaffolds (O’Brien et al., 2004). In addition, varying conditions
make it possible to modulate material properties, as shown by
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TABLE 3 | Summary of fabrication methods, advantages and disadvantages.
Fabrication technique Advantages Disadvantages
No true architecture
control
Mould casting Mould casting (Janik and Marzec,
2015)
– Simplicity and cost
– High cell survival
– Range of compatible materials
– Mechanical properties
– Scale up feasible
– Lowest architectural control
– Limited thickness
Pore-forming Solvent Casting, Particle Leaching,
Cryogelation (Janik and Marzec,
2015)
– Control of pore size
– No specialised equipment
– Cost
– Use of organic solvents
– Limited scaffold thickness
– Mechanical properties
– Time consuming leaching
– Limited pore architecture
Electrically
produced
SE (Liang et al., 2007) – Nanometer features
– Range of compatible materials
– Scaling up feasible
– Use of organic solvents
– Limited scaffold thickness




Weaving, Braiding, Knitting (Akbari
et al., 2016)
– Simple
– Scaling up feasible





Build & seed SLA (Melchels et al., 2010) – High architectural control
– Self-supporting process
– Only photosensitive polymers
– Remove supporting materials
– Use of UV light
– Toxicity of photoinitiator
– Specialised equipment (cost)
SLS (Mazzoli, 2013) – No solvents required
– High architectural control
– Self-supporting process
– Range of compatible materials
– High temperature
– Materials in powder form
– Rough surface
– Specialised equipment (cost)
MEW (Brown et al., 2011) – No solvents required
– Control over porosity, pore size and
fibre diameter
– High architectural control
– Limited thickness
– Range of available material
– Specialised equipment (cost)
FDM (Moroni et al., 2006) – No solvents required
– Speed of printing
– Good reproducibility





Bioprinting LGDW, LIFT, BioLP (Koch et al.,
2010; Gaebel et al., 2011; Hu et al.,
2017)
– Range of cells/biomaterials
– Single cell resolution
– Precise cell printing
– Low cell viability
– Limited 3D structure
– Time consuming
3DbioP (Zhang et al., 2015) – Range of cells/biomaterials
– High cell viability
– Process at room temperature
– Weak structural support
– Specialised equipment
– Multimaterial printing expensive
(multinozzle)
SE, Solution electrospinning; LGDW, Laser-guided direct writing; LIFT, Laser Induced Forward Transfer, BioLP, Bio-laser Printing; 3DbioP, 3D bioprinting; SLA,
Stereolithography; SLS, Selective laser sintering; MEW, Melt Electrospinning Writing; FDM, Fused deposition modelling.
Kim et al. (2015). In combination with gas foaming, Dattola et al.
fabricated a poly(vinyl) alcohol scaffold with pores within the
size of CMs, and Young’s Modulus similar to that of the native
cardiac ECM. These substrates are able to support the growth
and cardiac differentiation of hiPSC, albeit at apparently low rates
as demonstrated by the immunostaining for cardiac proteins
(Dattola et al., 2019).
Gas foaming has also been extensively applied to TE, though
its use within the cardiac field is not extensive. This technique
relies on the formation of bubbles, either by adding exogenous
agents such as sodium bicarbonate or through the inclusion of
enzymatic-driven reaction in the fabrication process (Mooney
et al., 1996). As the solution polymerises, these bubbles are
trapped inside. In consequence, the choice of foaming agent is
crucial for the later survival of cells. Although relatively simple to
implement, this technique provides no control over the degree of
interconnection between the formed pores or their directionality.
Porogen templating is based on the inclusion of salt crystals
in the pre-polymer solution. Similar to freeze drying, these
crystals will act as templates, creating an empty space (pore)
when the particles are leached out, in most cases by dissolving
in aqueous solution, weak bases or heating, (Thomson et al.,
1995) with sodium chloride being one of the most frequently
employed porogens. On the down side, limitations are related to
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low architectural control and suboptimal processing of porogens,
which might compromise biocompatibility as well as mechanical
properties. Salt leaching has not been as widely employed in cTE
as in other areas. Ganji et al. used table salt as a simple yet efficient
way to generate defined pores in polyurethane-based scaffolds
where gold nanotubes and nanowires were incorporated, thus
combining 3-dimensionality with the additional benefit of
electrical conductivity (Ganji et al., 2016). Biocompatibility tested
with H9c2 rat cardiomyoblasts showed a positive effect on
cell growth, though no hPSC-derived cells were tested. Other
examples have employed porogen templating for the fabrication
of porous polysaccharide-based vascular scaffolds and engineered
heart valves (Lavergne et al., 2012; Masoumi et al., 2014).
Thermally induced phase separation is based on the use
of temperature to induce the de-mixing of a homogeneous
polymer solution. The controlled change in temperature prompts
the formation of a polymer-rich and a polymer-poor phase,
which can be used to obtain an interconnected porous structure
(Nam and Park, 1999). Vozzi et al. synthesised the elastomer
polyesterurethane, and used thermal phase separation to create
a porous and biocompatible structure, which they functionalised
with fibronectin by NHS-EDC chemistry. Although material
properties were off the cardiac optimal range (in the order
of > 0.25 MPa), neonatal rat cardiac cells attached and grew
on the scaffolds, with specific modulation of gene expression.
However, no use of human cells was reported (Vozzi et al., 2018).
Electrically produced
Solution electrospinning (SE), on the other hand, was one of
the first and most employed fabrication modalities in the field.
In this technique, a polymer solution is subjected to a relatively
high electric field while it travels towards a collector plate.
This electric field causes the polymeric jet to whip, producing
very thin fibres of even sub-micron size, that can be collected
randomly or in an aligned fashion. For a review see Sensini and
Cristofolini (2018). In general, most SE applications produce low
thickness mats of (semi-)randomly arranged fibres of different
materials, though use of appliances such as a rotating mandrel
can increase alignment (Han et al., 2016). Although relying on
the use of potentially toxic solvents, SE has the advantage of being
open to a wide range of materials, both natural and synthetic
(Kitsara et al., 2017).
The concurrent use of SE with hPSC-derived cardiac cells
has not been widely explored but some remarkable examples
can be found. The group of Onnik Agbulut tested different
crosslinking times of a clinical-grade collagen electrospun
scaffold for the most suitable conditions for hiPSC-CM culture.
The resulting mats had fibres of 0.6-2.2 µm, with pores in
the range of 2-3 µm. After no deleterious effects were found
after mat implantation in animals, the mats were seeded with
hiPSC-CMs (106 per scaffold), and produced a significant
benefit when transplanted in a dilated cardiomyopathy model.
Importantly, scaffolds were compliant enough to allow the
generation of macroscopic contractions by the hiPSC-CMs
(Joanne et al., 2016). Sireesha et al. used a combination of the
elastomer poly[1,8-octanediol-co-(citric acid)-co-(sebacic acid)]
and fibrinogen to produce scaffolds with a sub-micron fibre
diameter, whose mechanical properties laid on the upper end
of cardiac elasticity (hundreds of kPa) and which showed good
biocompatibility with human CMs. However, no further tests
in animal models were performed (Sireesha et al., 2015). Khan
and co-workers electrospun polylactide-co-glycolide (PLGA) as
50 µm-thick aligned nanofibrous scaffolds, seeded with hiPSC-
CM, and compared the outcome versus conventional tissue
culture plastic surfaces. Results showed the scaffolds were able
to align the CMs, as well as inducing changes at the level of
functionality (Ca transients) and gene expression, though the
high stiffness of the mats (1-2 orders of magnitude above the
cardiac tissue) could have a negative impact (Khan et al., 2015).
On the other side of the coin, Han et al. assayed the capacity
of aligned electrospun mats made of PCL coated with matrigel
to induce hiPSC-CM maturation, showing a limited effect at the
functional level, but with some differences in gene expression
(Han et al., 2016).
Aside from employing different materials or combinations of
natural and synthetic polymers, SE offers increased possibilities
by modifying the properties of the resulting engineered
tissue by combination with nanoparticles or other fabrication
technologies. For example, the group of Tal Dvir built on his
previous work on the electrospinning of albumin (Fleischer et al.,
2014) to increase the anisotropy of the fabricated engineered
tissue. To do this, they employed a double strategy: they used laser
patterning to create micro-holes and unidirectional grooves, in
order to increase mass transport and cell alignment respectively,
and they stacked several layers of patterned mats, inspired
by the anisotropy found across the ventricular wall. In this
fashion, they also modulated the mechanical properties of the
layers, getting closer to human myocardial values. They did not,
however, test the stiffness of the resulting stacked construct, nor
populate it with human cells, using rat neonatal cardiac cells
instead (Fleischer et al., 2017). The group of Ali Khademhosseini
used poly(glycerol sebacate):gelatin (PG) solution where gelatin-
methacryloyl (GelMA)-coated carbon nanotubes had been
incorporated to electrospun aligned nanofibrous mats with
improved electrical properties, though at the cost of increased
stiffness (Kharaziha et al., 2014). This is similar to their previous
work with GelMA-embedded carbon nanotubes, (Shin et al.,
2013) with a significant effect on gene expression, structure and
functionality, but again no human cells were employed. Walker
et al. employed bio-ionic liquids to modulate the electrical
properties and adhesion strength of electrospun GelMA scaffolds,
assaying their in vitro and in vivo regenerative potential, though
no tissue was constructed (Walker et al., 2019). Again, mechanical
properties were affected. Recently, the group of Felix Engel
used SE to generate fibres combining the conductive polymer
polyaniline (PANi) with collagen/hyaluronic acid, producing
mats of suitable mechanical and electrical properties. Scaffolds
supported the attachment of hiPSC-CMs, which displayed
typical striations and contractions. Substrates incorporating
PANi induced a faster beating rate on hiPSC-CMs, though this
was not further explored (Roshanbinfar et al., 2020). All in all, SE
is a very versatile fabrication technique, and this is also increased
by the possibility of combining it with other materials and
technologies. However, it faces limitations related to the thickness
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 15 August 2020 | Volume 8 | Article 955
fbioe-08-00955 August 9, 2020 Time: 12:3 # 16
Montero et al. Human Cardiac Tissue Engineering
and dimensions of the final construct, as well as long-range
alignment capacity.
Textile-based fabrication
Historically speaking, weaving is one of the oldest fabrication
techniques and many (bio)materials can be processed by
knitting, weaving or braiding, (Akbari et al., 2016) giving rise
to new architectures and importantly, mechanical properties
unattainable for individual fibres. Curiously, these have not
been mainstream in the cTE field, with few studies combining
these fabrication methods with hPSC-derived cells. Though
their work cannot fully be categorised as textile-based, the
lab of Kevin K. Parker employed pull spinning to generate
nanofibrous scaffolds composed of PCL/Gelatin over an
ellipsoidal mandrel, mimicking the shape of an idealised
ventricle. After additional coating with the ECM protein
fibronectin, they seeded either neonatal cardiac rat cells or
hiPSC-CMs, generating scale-models of the heart with striking
functional properties (Macqueen et al., 2018).
Techniques With True Architecture Control
Additive manufacturing, also known as 3D printing, is one of
the technological revolutions of this century. It is based on the
building of a volumetric object from a computer aided design
(CAD), often in a layer-by-layer basis. Broadly speaking, we can
distinguish between bioprinting, where cells are also printed,
from the build & seed strategies, where the scaffold is first printed
and the cells incorporated in a subsequent step, either as a
standalone element or embedded in a hydrogel matrix. In any
case, the degree of control over the resulting structure is orders
of magnitude above what is achievable with the above-mentioned
technologies, with the exception of filament dimensions, with SE
being able to go into sub-micron diameter, albeit at the expense
of thickness and architecture.
3D Build and Seed
In this category we have gathered those additive manufacturing
technologies that do not allow the concurrent printing of
materials and cells, be it because they employ high temperature,
damaging lasers, toxic solvents or for other reasons. This
section includes selective laser sintering (SLS), consisting of
iteratively spreading layers of powdered materials and fusing
it together to achieve the programmed shape, (Duan et al.,
2010) stereolithography, where a bath with photosensitive
resin is selectively cured layer by layer with a UV laser or
similar power source, (Gauvin et al., 2012) or fused deposition
modelling (FDM), by which the printed polymer is melted
and deposited in layers in order to acquire the desired 3D
architecture (Moroni et al., 2006). All these technologies have
in common the need to first generate the architecture and
in a second step add the biologicals, with the only exception
of laser-curable materials in SLS. Although these technologies
are in increased demand for the building of prosthetics,
personalised solid implants or educational/surgery planning
models, (Giannopoulos et al., 2016) their application to cTE is
not widespread, especially in light of the increasing importance
of bioprinting techniques (next section).
A special note however must be dedicated to Melt
Electrowriting (MEW), a highly specialised additive
manufacturing technology (Brown et al., 2011). It works on
the same basis as SE, where a high voltage is applied between
a syringe tip and a grounded collector. In this case however,
the polymer is not dissolved, but melted. The superior stability
of the jet allows a highly controlled deposition of fibres, which
solidify in-flight or shortly upon collection. These, although
bigger in diameter than those from SE, are at least an order of
magnitude below what is usually attainable with 3D printing or
bioprinting (tens of µm in diameter). The polymer of choice
must be melted within the capacities of the printer, which
limits the range of the available polymers. Another significant
limitation is the achievable 3-dimensionality, which is usually
below the mm-range. The groups of Paul Dalton and Dietmar
Hutmacher have spearheaded its use (Bas et al., 2015, 2017;
Hochleitner et al., 2018) and have developed methods to
increase the thickness of the MEW scaffolds to almost one
cm, but again these are far from mainstream (Wunner et al.,
2018). The groups of Jos Malda and Joost Sluijter have been
the first ones to apply MEW to cTE. In their first approach,
they MEW-printed the hydroxyl-functionalised polyester,
(poly(hydroxymethylglycolide-co-ε-caprolactone) in orthogonal
patterns, and seeded them with human cardiac progenitor cells
(CPC) embedded in a collagen type I hydrogel. CPCs survived
well, with the scaffolds producing a significant alignment
(Castilho et al., 2017). In a further optimisation of the system,
Castilho et al. fabricated hexagonally patterned MEW scaffolds
with superior compliance, and seeded them with hiPSC-CMs.
Their results showed the superior biaxial mechanical properties
of the hexagonal designs, and their significant, positive effect on
cell alignment and gene expression. Moreover, these scaffolds
could be transplanted in a large animal (pig) after passing through
a catheter-like tube, paving the way for their future percutaneous
transplantation (Castilho et al., 2018). Finally, an auxetic patch,
that is, featuring a negative Poisson ratio, was recently fabricated
with MEW, and the conductive polymer polypyrrole in situ
polymerised on it, with electroconductive properties close to
those of the human myocardium (Olvera et al., 2020).
Bioprinting
The capacity to print human tissues on-demand has roused the
expectations of scientists, clinicians and patients alike, with a
range of modalities available. Laser-assisted bioprinting (LAB) for
example, features several methodologies. Laser-induced forward
transfer of material/ink (LIFT)(Koch et al., 2010) allows printing
with a single-cell resolution at high densities (up to 108 cells/ml)
(Gaebel et al., 2011). However, it requires selected materials
to gel relatively fast, which in practice restricts the range of
available materials, and can be technically challenging. 2 photon
polymerisation is a type of LAB with high spatial resolution (as
low as 70 nm) without the need for support structures (Hu et al.,
2017). Vaithilingam et al. employed this technique to fabricate
electroactive 3D architectures by incorporation of multi-walled
carbon nanotubes (CNTs). The mechanical properties were
however highly deviated from what has been described for
human cardiac tissue (GPa range). hiPSC-CMs were able to
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survive and, after the application of electrical stimulation, a
significant effect on sarcomere length was found (Vaithilingam
et al., 2019). There are other printing technologies based on
LAB, such as Biological Laser Printing and Laser Guided Direct
Writing, (Odde and Renn, 2000; Barron et al., 2004) but no
reports on these include hiPSC-derived cardiac cells.
Extrusion-based bioprinting is probably the best-known
bioprinting method: a bioink containing both cells and the
biomaterial is extruded through a nozzle onto a motorised
collector. The coordination between the gelation of the bioink
and its deposition permits the generation of thick tissues.
A range of nozzles, including pneumatic, screw- or plunger-
based, as well as inks, is available. However, the material
properties of the latter are fundamental, as shear stress generated
upon printing highly impacts cell viability (Jungst et al.,
2016). Some strategies, like in situ crosslinking of the bioink
immediately prior to its deposition, (Ouyang et al., 2017)
are being developed to overcome these and other limitations.
Extrusion-based bioprinting has been extensively researched
in the cTE field. Jang et al. employed a multi-nozzle printer
to generate tissues with 2 decellularised cardiac ECM-based
bioinks reinforced with a thermoplastic (PCL) backbone. One
of the bioinks contained human CPCs (c-kit-positive), and the
other mesenchymal stem cells (MSC) and pro-angiogenic factors
(VEGF). The application of this patch in a rat model of disease
demonstrated a rapid vascularisation as well as a significant
benefit at the functional and histological levels. However, no
new contractile tissue was formed (Jang et al., 2017). Zhang and
coworkers employed a more advanced strategy, where they used
coaxial printing to pattern human umbilical vein endothelial
cells (HUVECs) in a ink containing alginate, GelMA and the
UV-curable photoinitiator Irgacure. The mixture was quickly
crosslinked by CaCl2 from the outer sheath, and further gelled
by exposure to UV light (for alginate and GelMA respectively)
(Zhang Y. S. et al., 2016). HUVECs migrated to the outer border
of the printed structures, forming 3D vessel-like structures over
a period of 15 days, after which neonatal rat CMs were added to
complete the tissue. Izadifar et al. explored varying the electrical
properties of the generated tissues by incorporating alginate-
coated carbon nanotubes (CNT) to methacrylated collagen. The
system displayed as expected enhanced electrical properties, once
more at the expense of becoming stiffer, though within acceptable
values, and was able to support the growth of human coronary
artery endothelial cells. No CMs were employed (Izadifar et al.,
2018). Maiullari and coworkers applied a different version of
extrusion printing termed microfluidic printing, to generate
vascularised engineered tissues combining HUVECs and hiPSC-
CMs (Maiullari et al., 2018). The bioartificial myocardium
was fabricated with a bioink combining alginate for a rapid
crosslinking, and polyethylene glycol (PEG) monoacrylate-
fibrinogen, for UV-curing and cell adhesion. These tissues were
tested in vivo, were the presence of vascular cells was able to
promote integration with the recipient vascular system. Zhu
et al. formulated a bioink with capacity to electrically influence
neonatal rat CMs by incorporating gold nanorods in GelMA.
Thick constructs were generated, although cell viability was below
80% in most cases. This is extremely relevant if we take into
account that CMs are non-proliferative cells, so no re-growth is
likely to occur (Zhu et al., 2017).
Freeform embedding of suspended hydrogels (FRESH) is one
of most exciting 3D bioprinting methods (Hinton et al., 2015).
Here, the biomaterial ink or bioink of choice is printed within
the support of another hydrogel serving as a temporary support.
Noor and co-workers developed a personalised hydrogel ink from
human decellularised omental tissue, which could be printed into
complex structures using FRESH. They used it in combination
with hiPSC which they differentiated within the matrix into
beating, perfused cardiac mini-tissues (Noor et al., 2019). Lastly,
the Feinberg group used FRESH to accurately (20 µm resolution)
3D print different components of the human heart with collagen,
including a model of the left ventricle on the scale of the
neonatal organ, incorporating hESC-CMs (Lee et al., 2019). These
engineered tissues displayed synchronised functional activity.
Finally, some the applications build tissues without the use
of biomaterials. This includes the additive manufacturing with
spheroids, as demonstrated by Arai et al., where they combined
commercially available hPSC-CMs with HUVECs and dermal
fibroblasts to generate the spheroids, organised in a tubular 3D
structure with a bioprinter (Arai et al., 2018). However, the
authors used a needle array to provide initial transient support for
their structures, which in the end played the role of a scaffolding
material. Recently, Ayan et al. reported a novel strategy, termed
aspiration-assisted bioprinting, relying on the aspiration of 3D
spheroids and their precise deposition in 3D. This could also be
combined with FRESH, but no use of hiPSC-derived cardiac cells
was reported (Ayan et al., 2020).
CLINICAL TRANSLATION OF
hPSC-BASED cTE STRATEGIES
Survival post-cardiac ischemia has raised with advances in
the cardiology and cardiovascular surgery areas, as well as
through the development of new drugs in the last decades. This
includes the application of reperfusion by percutaneous coronary
intervention, anticoagulants and antithrombotics, amongst
others. Though cTE has potential to address different cardiac
conditions, its main activity has been directed towards the loss of
viable myocardium by supplying new one, engineered in the lab.
In stark contrast to the short time elapsing between the
first reports on regenerative medicine with adult stem cells
and their first in-human application (reviewed in Banerjee
et al., 2018) cTE with hPSCs has scarcely reached the clinical
arena. Be it because both scientists and clinicians have learnt
from past experiences or because translation presents additional
complications, (Desgres and Menasché, 2019; Ghaemi et al.,
2019; Ke and Murphy, 2019) clinical application is yet to
become a reality. The technology faces challenges in the
area of regulation, where reprogrammed cells under GMP-
conditions are not widely derived, in logistics, with the size of
engineered tissues in most instances requiring open chest surgery,
and in economic terms. However, progress is being made.
Tiburcy et al., created an engineered human myocardium with
advanced structural and functional maturation by combining
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hPSC-derived cells with collagen type I (Tiburcy et al., 2017).
Their work, standing on the shoulders of decade-long progress,
(Zimmermann et al., 2002, 2006) demonstrated the building
of human-scale relevant tissues (3.5 × 3.4 cm, containing
40 million CMs) under defined conditions and their pre-
clinical safety assessment in rats, though no large animal
testing was performed. The group of Prof Bursac applied
dynamic culture conditions to improve the maturation of a
patch formed from hiPSC-derived cardiac cells in a fibrin
matrix. Although they achieved human adult-like electrical
properties (e.g., conduction velocity) and formed large grafts
when transplanted into rodents, the use of matrigel in the
forming mixture precludes further translation (Shadrin et al.,
2017; Jackman et al., 2018). In addition, myocytes were mostly
randomly arrayed, which added to the low thickness of the
grafts precludes any efficient and substantial force generation,
and therefore makes providing contractile support to diseased
hearts difficult.
Menasche et al. performed the first clinical case of an
hPSC-based patch in 2015, transplanting a 20 cm2 fibrin-
based tissue. This patch contained 4 million hESC-derived Isl+
SSEA1+ CPCs and was implanted epicardially in a 68-year-
old patient with advanced heart failure. Concomitant to the
implantation of the patch, a coronary artery bypass was also
performed. After 3 months, the patient had better symptoms,
and there was improved evidence in the echocardiogram
too (form akinetic to moderately hypokinetic). Moreover, no
adverse effect was observed (Menasché et al., 2015). This was
part of the first clinical trial carried out with six patients
suffering from advanced IHD (NCT02057900), called ESCORT.
The aim of the trial was to demonstrate the safety of
the patch at 1 year. All patients improved symptomatically,
with four showing an increased systolic motion. One died
early in the post-operative period from treatment-unrelated
comorbidities and another after in 22 months due to heart failure
(Menasché et al., 2018).
Japan has made huge efforts to spearhead research in the
hiPSC field, and has one of the most streamlined regulatory
frameworks (see Cyranoski, 2019 for a comment). It has recently
started the first clinical trial of hiPSC-CM transplant in ischemic
heart dysfunction. The study will deliver 100 million hiPSC-CMs
in the form of a cell sheet of 4 × 5 × 0.1 cm (Kawamura et al.,
2017). The aim of the study is to evaluate efficacy and safety of
the treatment in a total of 10 patients (Cyranoski, 2018).
Overall, clinical applications of hPSC-based cardiac
engineered tissues, though scarce, are starting to emerge.
However, the scientific and logistic/economic concerns
mentioned above need addressing further before any of
these technologies reach the clinical arena.
CONCLUSION AND OUTLOOK
The capacity to fabricate human myocardium in the laboratory
is no longer restricted to science fiction. Recent breakthroughs
such as cell reprogramming and 3D (bio)printing have shifted
the question from ‘Can we do it?’ to ‘How do we want to do it?’.
However, lessons from its predecessor in the area of regenerative
medicine should teach us the value of caution. Crucial questions
remain, some of which include the following:
-What are the most suitable components for building an
engineered myocardium? Of course, this absolutely depends on
the application/pathology we are targeting. If the objective is
to reconstruct the post-disease myocardium, especially in cases
when muscular mass has been loss (as IHD), this will require
new CMs, alongside new vessels and support cells. Although
not supplying new CMs might still be beneficial, it will not
regenerate the tissue to pre-disease levels. So far, only hPSCs
can produce the required cells in sufficiently large amounts,
and whether it is better to use fully differentiated cells or
progenitors is still an open question. Regarding the ECM-mimics,
the current state can seem confusing. All reported (bio)material
formulations seem to provide a benefit (Table 2). It is plausible
that the most important factor is for the material to recapitulate
the mechanical environment of cardiac tissue long enough for
delivered cells to build their own structure. Also, although
collagen type I has repeatedly been positioned as being the
main component of the cardiac ECM, this does not account
for all its mechanical capacities, nor it is as abundant as the
levels supplemented in engineered tissues. Probably, cost and
translation capacity will have much to say here. Lastly, regarding
the fabrication mode, though 3D bioprinting has captivated
both scientists and the wider public, its actual ability to deliver
tissues able to withstand the mechanical forces in play in the
human myocardium is far from optimal in most cases. Fibre
reinforcement might be a solution to this, but remains to be
fully tested in a human scale. In addition, recent technical
developments such as 4D printing or cyborganics will certainly
widen the scope of possibilities at hand (Tamay et al., 2019;
Orive et al., 2020).
– How is translation going to happen? The hurdles are
significant, (Desgres and Menasché, 2019; Ghaemi et al., 2019)
not only due to the use of genetically modified cells (hiPSCs),
exogenous materials and complex equipment, but also because
in order to attain sufficient functional capacity, it is likely that
some lengthy period of in vitro electromechanical maturation
must be implemented. Also, no standard equipment currently
exists to apply this to a human-scale tissue. In this area, it is
crucial that biomedical researchers work alongside lawmakers.
Cell therapy mostly relied on an autologous application of a
non-cultured material, which smoothened its approval. Tissue
engineering applications based on hiPSC products are highly
promising but are impeded by stringent regulations. Japan has
spearheaded hiPSC translation as a national flagship (Azuma
and Yamanaka, 2016). Although some consider this too loose,
it is clear that unless scientists provide a clear direction and get
themselves involved in depth in the regulatory process, advances
will be limited.
– Will costs be sensible? hiPSC culture and differentiation
are expensive. Additive manufacturing is expensive. GMP-
grade materials are expensive. hiPSC line derivation costs
between €4000-8000 depending on the provider, multi-nozzle
3D bioprinters are usually budgeted above €30000, and some
medical-grade materials as human collagen type I are prohibitive
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(> €200 per 100 µg). Highly trained personnel costs need
to be added on top of this, as well as the cost of hiPSC
expansion and differentiation. The cost of a heart transplant in
the United States is above $150000 (including 120-day medical
care), with Left Ventricular Assist Devices (LVADs), employed
for patients with end stage heart failure as a bridge to transplant
(and now trialled as destination therapy) are estimated to cost
even more (see Miller et al., 2013 for a concise review). If
economic issues are not addressed from day one, we run the
risk of ending up with a highly effective therapy only that
very few people can pay for. Large-scale production of hiPSC-
derived cells has been demonstrated and will no doubt help
decrease costs (Abecasis et al., 2017; Halloin et al., 2019; Buikema
et al., 2020). Strategies to induce hiPSC-CM division would
significantly improve the economics.
– Will the new therapy be safe? hPSCs have been marred
by concerns related to persistence of pluripotent cells after
differentiation and the subsequent risk of teratoma formation.
But also, the new tissue must conform to the host’s electrical
activity. Again, lessons from Cell Therapy call for caution
(Menasché et al., 2008). Advanced genomics and other analysis
tools not available 10 years ago will significantly enhance the
safety analysis and help researchers and clinicians along the way
(Wang Z. et al., 2020).
– Are the aims achievable? The objective of cTE is to generate
new human myocardium whose properties and functionality are
similar to its natural counterpart, but that might not be achievable
within a sensible timeframe. Human cardiac maturation advances
significantly after birth but continues throughout the first
decades of life. Current advanced methods for maturation,
like those based on electromechanical stimulation, do not
achieve anything even close to adult properties. However,
it is plausible that only a minimal maturity is needed in
order to avoid lethal arrhythmias, as hPSC-CMs are reported
to undergo maturation after transplantation in the heart
(Kadota et al., 2017).
– What is the state of non-therapeutic applications? Though
the aim of cTE within regenerative medicine is directed
towards treatment, bioartificial human myocardium is becoming
increasingly relevant with respect to other applications such
as disease modelling and drug testing (Vunjak-Novakovic
et al., 2014; Sharma et al., 2020), where the scale of the
fabricated tissues is not an issue. In drug testing, the CiPA
initiative has already pointed to the relevance of hiPSC-
CMs, (Millard et al., 2018) especially given cardiac side
effects are one of the main reasons for drug withdrawal,
and there is no primary source of human CMs available
(Laverty et al., 2011). Current efforts have already proven the
capacity of cTE-based systems to better recapitulate physiological
human drug response [reviewed in Kadota et al. (2017)
and Millard et al. (2018), or to generate chamber-specific
microtissues (Zhao et al., 2019)]. Translation towards industrial
and clinical testing is envisioned to be more straightforward
and immediate.
As can be seen, the challenges ahead are not minor. However,
humankind has never been closer to achieving success in
tissue fabrication. Whole functional heart generation in the
laboratory, though frequently dreamt of, is still not achievable,
as severe physiological and technical roadblocks remain in
place. Challenges include ensuring adequate vascularisation,
electromechanical coupling over long distances, atrioventricular
delay, autonomous nervous system innervation or designing
materials both biocompatible but capable of supporting the
strong mechanics of a whole heart, amongst others. At this
extraordinary moment, it is crucial for scientists, clinicians, and
lay people to stay focused and deliver.
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